Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Allergy Immunotherapy Market

Allergy Immunotherapy Market Share

Report ID: GMI11114
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Allergy Immunotherapy Market Share

The competitive landscape in the market is diverse and highly competitive, driven by global pharmaceutical giants as well as biotechnology firms. Major players, such as Allergy Therapeutics, dominate the market space by adopting various growth strategies such as strategic partnerships, mergers & acquisitions, and collaborations to sustain their market position. Further, these companies are currently focusing on expanding their presence in emerging markets, such as those in Asia Pacific countries.

Allergy Immunotherapy Market Companies

Prominent players operating in the Allergy Immunotherapy industry include:

Adamis Pharmaceuticals Corporation
Aimmune Therapeutics
ALK-Abelló A/S
Allergy Therapeutics
ASIT Biotech
Circassia Pharmaceuticals plc
DESENTUM OY
DVB Technologies SA
HAL Allergy B.V.
HollisterStier Allergy
LETI Pharma
Merck KGaA
Mylan N.V.
Stallergenes Greer plc
Zhejiang Wolwo Bio-pharmaceutical Co., Ltd, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global allergy immunotherapy industry was valued at USD 1.9 billion in 2023 and is anticipated to register 8.5% CAGR between 2024 and 2032 due to rising healthcare expenditure and consumer awareness regarding the availability of advanced treatments.

The hospital pharmacy segment in the market is anticipated to reach USD 2.1 billion by 2032 due to its key role in managing specialized medications, facilitating clinical trials, and coordinating with allergists for optimal treatment.

North America allergy immunotherapy market accounted for USD 780.5 million in 2023, attributed to the high prevalence of allergy conditions, high patient awareness and favorable reimbursement policies.

Adamis Pharmaceuticals Corporation, Aimmune Therapeutics, ALK-Abell